Stability of serum interleukin-10 levels during the menstrual cycle

American Journal of Reproductive Immunology

Volumn 38, Issue 5, 1997, Pages 339-342

  Maskill, Joanna K ^a   Laird, Susan M ^a   Okon, M ^b   Li, T C ^b   Blakemore, Alexandra I F ^a  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^b JESSOP HOSPITAL FOR WOMEN   (United Kingdom)

Author keywords

Cytokines; Interleukins; Women

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 10; LUTEINIZING HORMONE;

ADULT; ARTICLE; FEMALE; HUMAN; LUTEINIZING HORMONE RELEASE; MENSTRUAL CYCLE; NORMAL HUMAN; PREGNANCY; PRIORITY JOURNAL;

EID: 0030875922     PISSN: 87558920     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0897.1997.tb00309.x     Document Type: Article

References (14)

1. Howard M, O'Garra A, Ishida H, de Waal Malefyt R, de Vries J: Biological properties of interleukin 10. J Clin Immunol 1992; 12:239-247.
2. Jenkins JK, Malyak M, Arend WP: The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1 beta production in human monocytes and neutrophils. Lymphokine Cytokine Res 1994; 13:47-54.
3. de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, Johnson K, Kastelein R, Yssel H, de Vries JE: Interleukin-10 (IL-10) and viral IL-10 strongly reduce antigen-specific T-cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174:915-924.
4. Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu DH, Kastelein R, Moore KW, Banchereau J: IL-10 is a potent growth differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992; 89:1890-1893.
5. Cush JJ, Splawski JB, Thomas R, McFarlin JE, Schulze-Koops H, Davis LS, Fujita K, Lipsky PE: Elevated interleukin-10 levels in patients with Rheumatoid Arthritis. Arthritis Rheum 1995; 38:96-104.
6. Maskill JK, Gordon C, Blakemore AIF; Elevated serum interleukin-10 is associated with increased activity of systemic lupus erythematosus. Immunology 1996; 89S1:78.
7. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M: Continuous administration of anti-interleukin-10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994; 179:305-310.
8. Lynch EA, Dinarello CA, Cannon JG: Gender differences in IL-1α, IL-1β and IL-1 receptor antagonist secretion from mononuclear cells and urinary excretion. J Immunol 1994; 153:300-306.
9. Li TC, Mackenna AJ, Roberts R: The techniques and complications of outpatient uterine washings in the assessment of endometrial function. Hum Reprod 1993; 8:343-346.
10. Cannon JG, Dinarello CA: Increased plasma interleukin-1 activity in women after ovulation. Science 1985; 227:1247-1249.
11. Leibovici L, Alpert G, Kalter-Lelbovici O, Danon YL: Risk factor for recurrence of symptomatic urinary tract infection in young women. Isr J Med Sci 1989; 25:110-111.
12. Senie RT, Rosen PP, Rhodes P, Lesser ML: Timing of breast cancer excision during the menstrual cycle influences duration of disease free survival. Ann Intern Med 1991; 115:337-342.
13. Krasnow JS, Tollerud DJ, Naus G, DeLoia JA: Endometrial Th2 cytokine expression throughout the menstrual cycle and early pregnancy. Hum Reprod 1996; 11:1747-1754.
14. Greig PC, Herbert WNP, Robinette BL, Teot LA: Amniotic-fluid interleukin-10 concentrations increase through pregnancy and are elevated in patients with preterm labor associated with intrauterine infection. Am J Obstet Gynecol 1995; 173:1223-1227.